ATU iHub client company InVera Medical has announced positive 12-month results from its pilot clinical study of the InVera Infusion Device for the treatment of Chronic Venous Disease (CVD). The findings were presented at the Charing Cross Symposium in London by Dr. Lowell Kabnick, former President of the American Venous Forum and head of InVera’s Medical Advisory Board.
The study showed 90% vein closure rates in treated patients after 12 months, alongside statistically significant improvements in patient symptoms and quality of life measures. Researchers also reported no serious adverse events or cases of deep vein thrombosis during the study period.
The InVera Infusion Device offers a non-thermal alternative to traditional vein ablation procedures, eliminating the need for multiple painful anesthetic injections commonly associated with thermal techniques. The device recently achieved both FDA 510(k) clearance and CE Mark approval, with the company now preparing for limited market release across select US and European centres.
Founded in 2018, InVera Medical develops minimally invasive catheter-based technologies aimed at improving treatment outcomes and patient experience in vein disease care.